| Page 42 | Cafepharma

You are here

Primary tabs

Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C

Post date: September 24, 2018 - 9:22am

Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma

Post date: September 21, 2018 - 9:42am

Ex-Novartis Chief Joins uBiome to Help Launch Discovery and Development Business

Post date: September 21, 2018 - 9:15am

MicuRx Recieves Fast Track and QIDP Designations for MRSA Antiobiotics

Post date: September 21, 2018 - 9:05am

Microbiome Report for Week Ending 9/15/18

Post date: September 20, 2018 - 9:54am

BeiGene Presents Encouraging Results in Ph I Trial of Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors

Post date: September 20, 2018 - 9:47am

Amicus Therapeutics Ramps Up Gene Therapy Portfolio with Acquisition of 10 Programs

Post date: September 20, 2018 - 9:31am

Pfizer's Pneumococcal Conjugate Vaccine Awarded Breakthrough Therapy Designation

Post date: September 20, 2018 - 9:08am

MaaT Pharma Presents Analysis of Its First-in-Class High Diversity Microbiome Therapeutic

Post date: September 19, 2018 - 10:57pm

Argenx To Raise $300 million in U.S. public offering

Post date: September 19, 2018 - 9:32am

Pages